

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously presented) A composition comprising a MTB39 antigen, having an amino acid sequence of SEQ ID NO:8 or 26, or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex, and a MTB32A antigen, having an amino acid sequence of SEQ ID NO:4, or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex.
2. (Previously presented) The composition of claim 1, comprising a MTB39 antigen, having an amino acid sequence of SEQ ID NO:8 or 26, or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex, and a polypeptide comprising at least 205 amino acids of the N-terminus of a MTB32A antigen (SEQ ID NO:4) from a *Mycobacterium* species of the tuberculosis complex.
3. (Previously presented) The composition of claim 2, further comprising a polypeptide comprising at least about 132 amino acids from the C-terminus of MTB32A antigen (SEQ ID NO:4) from a *Mycobacterium* species of the tuberculosis complex.
4. (Original) The composition of claims 1, 2, or 3, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.
5. (Previously presented) The composition of claim 4, wherein the fusion polypeptide has the amino acid sequence of MTB59F (SEQ ID NO:10).
6. (Currently amended) The composition of claim 4, wherein the fusion polypeptide is encoded by a polynucleotide that hybridizes under stringent hybridization conditions to the complement of the nucleotide sequence of MTB72F (SEQ ID NO:11), wherein

the stringent hybridization conditions comprise an incubation in 50% formamide, 5 x SSC, and 1% SDS at 42°C or in 5 x SSC and 1% SDS at 65°C, with a wash in 0.2 x SSC and 0.1% SDS at 65°C.

7. (Original) The composition of claim 4, wherein the antigens are covalently linked via a chemical linker.
8. (Original) The composition of claim 7, wherein the chemical linker is an amino acid linker.
9. (Previously presented) The composition of claim 1, further comprising at least one additional antigen from a *Mycobacterium* species of the tuberculosis complex, wherein the antigen is selected from the group consisting of MTB8.4 antigen (SEQ ID NO:14), MTB9.8 antigen (SEQ ID NO:16), MTB9.9A MTB9.9 antigen (SEQ ID NO:18), MTB40 antigen (SEQ ID NO:20), MTB41 antigen (SEQ ID NO:22), ESAT-6 antigen (SEQ ID NO:24), MTB85 complex antigen (SEQ ID NO:30), or  $\alpha$ -crystalline antigen (SEQ ID NO:28), or an immunogenic fragment thereof.
10. (Original) The composition of claim 1, further comprising an adjuvant.
11. (Original) The composition of claim 10, wherein the adjuvant comprises QS21 and MPL.
12. (Original) The composition of claim 10, wherein the adjuvant is selected from the group consisting of AS2, ENHANZYN, MPL, QS21, CWS, TDM, AGP, CPG, Leif, saponin, and saponin mimetics.
13. (Original) The composition of claim 1, further comprising BCG.
14. (Original) The composition of claim 1, further comprising an NS1 antigen or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex.

15. (Original) The composition of claim 1, wherein the *Mycobacterium* species is *Mycobacterium tuberculosis*.

16-54. (Canceled)

55. (Previously presented) The composition of claim 6, further comprising at least one additional antigen from a *Mycobacterium* species of the tuberculosis complex, wherein the antigen is selected from the group consisting of MTB8.4 antigen (SEQ ID NO:14), MTB9.8 antigen (SEQ ID NO:16), MTB9.9A antigen (SEQ ID NO:18), MTB40 antigen (SEQ ID NO:20), MTB41 antigen (SEQ ID NO:22), ESAT-6 antigen (SEQ ID NO:24), MTB85 complex antigen (SEQ ID NO:30), or  $\alpha$ -crystalline antigen (SEQ ID NO:28), or an immunogenic fragment thereof.

56. (Previously presented) The composition of claim 6, further comprising an adjuvant.

57. (Previously presented) The composition of claim 56, wherein the adjuvant comprises QS21 and MPL.

58. (Previously presented) The composition of claim 56, wherein the adjuvant is selected from the group consisting of AS2, ENHANZYN, MPL, QS21, CWS, TDM, AGP, CPG, Leif, saponin, and saponin mimetics.

59. (Previously presented) The composition of claim 6, further comprising BCG.

60. (Previously presented) The composition of claim 6, further comprising an NS1 antigen or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex.

61. (Previously presented) The composition of claim 55, wherein the *Mycobacterium* species is *Mycobacterium tuberculosis*.

62. (Previously presented) The composition of claim 6, wherein the fusion polypeptide has the amino acid sequence of MTB72F (SEQ ID NO:12).

63. (Currently amended) A composition comprising BCG and a fusion polypeptide encoded by a polynucleotide that hybridizes under stringent hybridization conditions to the complement of the nucleotide sequence of MTB72F (SEQ ID NO:11), wherein the stringent hybridization conditions comprise an incubation in 50% formamide, 5 x SSC, and 1% SDS at 42°C or in 5 x SSC and 1% SDS at 65°C, with a wash in 0.2 x SSC and 0.1% SDS at 65°C.

64. (Previously presented) A composition comprising BCG and a fusion polypeptide that comprises an amino acid sequence of MTB72F (SEQ ID NO:12).

65. (Previously presented) The composition of claim 64, wherein the fusion polypeptide consists of the amino acid sequence of MTB72F (SEQ ID NO:12).

66. (Previously presented) The composition of claim 64, wherein BCG recombinantly expresses the fusion polypeptide.

67. (Canceled)